Objective: To evaluate the antihyperglycemic effect of Talapotaka Churna in experimental animals, Talapotaka Churna was prepared, containing Avartaki (Cassia auriculata), Amalaki (Emblica officinalis), Haridra (Curcuma longa), and Daruharidra (Berberis aristata). Materials and Methods: Talapotaka Churna was prepared by the standard procedure of Churna Kalpana. Hyperglycemia was induced to create an equivalent to the diabetic state by giving streptozotocin (STZ) solution (intraperitoneal) 35 mg/kg. After assessment of hyperglycemia as an approximate induction of diabetes, group of animals (IV and V) were treated with doses 300 and 600 mg/kg of Talapotaka Churna. For treatment comparison, Group III animals were treated with a standard hypoglycemic drug, glibenclamide 10 mg/kg. Blood sugar, the level was estimated by glucometer on the 7 th , 14 th , 21 st , and 28 th day. Results: Talapotaka Churna produced a significantly lowering of fasting blood glucose with various doses in STZ-induced diabetic rats. In a 4-week study, Talapotaka Churna produced a significant reduction in blood glucose compared to glibenclamide. Conclusion: Talapotaka Churna and glibenclamide significantly lowered blood glucose level. The results were found more significant with respect to treatment days in this in vivo comparative study.
INTRODUCTION

D
iabetes mellitus (DM) is a leading metabolic disorder with clinical syndrome since antiquity involving various organ systems and marked by chronic hyperglycemia. DM continues to be a worldwide health problem and is a major healthcare puzzle, as it becomes a serious threat to humankind due to its secondary complications of kidney failure, blindness, and neuropathy, with its associated high health-care costs and challenge for all physicians. The prevalence of diabetes for all age groups worldwide was estimated 8.3% (387 million) in the 21 st century and is estimated to be 592 million by 2035. [1, 2] In Ayurveda, Prameha/Madhumeha can be considered as DM by different perspectives based on clinical symptoms and attempts have been made by Ayurvedic physicians and researchers to treat these two entities using classical formulations mentioned in Prameha Chikitsa. [3] Worldwide, people are successfully using and trusting herbal medicine for the treatment of various health problems. Many of the diabetic patients are getting side effect due to allopathic medication, so now patients are relying on alternative therapies with antihyperglycemic effects. This comes as no surprise since alternative treatments have been most widely used in chronic diseases, which may be only partially alleviated by conventional treatment. Herbal medications are the most commonly used alternative therapy for lowering blood sugar. The interest in herbal drug research continues with an expectation that someday or other, we would be able to bring a safer, efficacious, and more effective compound with all the desired parameters of a drug that could replace the synthetic medicines. The plant has definite promises in the management of diabetes. Isolation and identification of active chemical principle from plant and preparation of standardized dosage can play a key role in the management of diabetes. Besides this for the global acceptance, the herbal remedies are very easily accepted by the society. 
MATERIALS AND METHODS
Selection and Collection of Plant Materials
The formulation contains 4 ingredients. Among these, Avartaki was collected from the peripheral region of Satara district, Maharashtra, India. The rest 3 raw drug samples were procured from Gola Dinanath (Raw drug market), Varanasi, Uttar Pradesh, India. All the collected samples were pharmacognostically identified and confirmed in the Department of Dravyaguna, Faculty of Ayurveda, IMS, Banaras Hindu University, Varanasi.
Churna Preparation
The collected plant materials of Talapotaka Churna were cleaned and dried in the sunlight. The dried plant material was then ground into a fine powder using a mechanical pulverizer in Ayurvedic Pharmacy, Banaras Hindu University, Varanasi, India. This sample was used for antidiabetic study. 
Chemicals
Experimental Protocol
The experimental study was conducted at the Department of Pharmacology, IMS, BHU. 30 animals were divided into five groups and were kept under standard laboratory condition during the study. The groups were named normal control (NC) (Group I), diabetic control (DC), non-treated (Group II), diabetic standard group (Group III), and the two test groups of Talapotaka Churna in different doses Groups IV (300 mg) and V (600 mg).
On day t = −1, before induction of hyperglycemia as an approximate induction of DM, the rats were kept fasting from all food; only water was given. Immediately before injection, STZ was dissolved in 50 mg of sodium citrate buffer (pH 4.5) to a final concentration of 10 mg/ml. The STZ solution was freshly prepared for each rat and was injected within 5 min after being dissolved.
Hyperglycemia was induced (in-Group II to V) by STZ solution intraperitoneal using a dose of 35 mg/kg through insulin syringes. After 72 h, blood sugar level was measured by optimum exceed glucometer (Abbott). For investigation of blood glucose, blood of rats was withdrawn through a tail central vein. Hyperglycemia was confirmed by the elevated glucose level in the blood by glucometer, determined after 72 h. [7] On the 7 th day after confirmation of hyperglycemia, animals of Groups IV and V were treated with different doses of Talapotaka Churna. Animals of Group III were treated with hypoglycemic drug glibenclamide 10 mg/kg. Glibenclamide stimulates the pancreatic beta cells of the pancreas and increasing the sensitivity of the peripheral tissue to insulin. Data of blood sugar were collected every 7 th day of duration for 4 weeks and compared among groups.
Dose Schedule
About 30 Charles Foster rats were divided into five groups, namely, NC (Group I), DC (Group II), standard group treated with glibenclamide in dose of 10 mg/kg body weight (Group III), and treated group with Talapotaka Churna (Group IV and Group V) in the dose of 300 mg/kg and 600 mg/kg body weight, respectively. The test drugs Talapotaka Churna and standard drug glibenclamide were administered according to the body weight of the animal by oral route with the help of an intragastric tube.
Statistical Analysis
Statistical analysis of data was performed using SPSS 16.0 and one-way analysis of variance. Results were expressed as mean ± standard deviation from six rats in each group. P < 0.05 was considered statistically significant, and P < 0.001 was considered highly statistically significant in the results of this study.
RESULTS
The baseline value in all five groups of albino rats showed that the fasting blood glucose (FBG) levels were within normal limits. The first task was to create an experimental model of hyperglycemia. A single dose (35 mg/kg) of STZ was administered to Groups II-V, leaving Group I as an NC. Hyperglycemia was significantly induced compared to NC FBG after 72 h and was confirmed on the 7 th day following STZ administration [ Figure 1 ].
The second task was to evaluate dose-dependence on reduction in blood glucose of experimentally-hyperglycemic rats in our diabetic model. The stock solution was prepared freshly by the adequate quantity of distilled water with the samples of Talapotaka Churna was given at the doses of 300 mg/kg and 600 mg/kg, to each of six rats in each of the two groups. Results are shown in Table 1 , and demonstrated a dose-dependent reduction, with 300 mg/kg and 600 mg/kg showing the greatest reduction in blood glucose level. Talapotaka Churna produced a maximum reduction of blood glucose of 55% (P < 0.001) and 53% (P < 0.001) 1 h with doses of 300 and 600 mg/kg, respectively [ Figure 2 ].
The next task was to compare a dose of Talapotaka Churna with a standard antidiabetic drug, glibenclamide. In a 4-week study, Talapotaka Churna produced a significant reduction in blood glucose compared to glibenclamide as shown in Table 1 . Glibenclamide (10 mg/kg) produced a maximum reduction of FBG 63% (1 h, P < 0.001) compared to DC Group II [ Figure 3 ].
The results indicate a prolonged action in a reduction in blood glucose by Talapotaka Churna and are probably mediated through enhanced secretion of insulin from β-cells of Langerhans or through an extrapancreatic mechanism. Talapotaka Churna produces a significant effect with various doses in STZ-induced diabetic rats. In the treated group for 4 weeks, significant reduction of FBG level was observed.
Mean and standard deviation of sugar of normal group and various treatment groups on day 0, 7, 14, 21, and 28 was determined and show in Table 1 . Mean sugar in NC group was much smaller as compared to other groups. Mean sugar level decreased successively on different days. The intergroup comparison was statistically highly significant on each 7 th day observation. Post-hoc test for pair wise group comparison was also applied, and pairs were found statistically significant as shown in Table 1 .
DISCUSSION
Talapotaka Churna is a poly-herbal formulation containing four herbs, each reported in the Ayurvedic classics to have the action of reducing Prameha. [8] [9] [10] [11] These herbs have also been studied in modern science and showed a significant reduction in blood glucose levels in DM animal models. Gupta et al. (2010) found Cassia auriculata leaf extract has insulinogenic action in STZ-induced diabetic rats. [12] Latha et al. (2003) found C. auriculata L. flower extract suppresses enhanced gluconeogenesis and enhances utilization of glucose through increased glycolysis in STZ-induced diabetic rats. [13] Abesundara et al. (2004) showed that C. auriculata flower extract exerts a strong antihyperglycemic effect in rats comparable to the therapeutic drug acarbose. [14] Patel et al. (2011) found fruit juice of Emblica officinalis showed decreased glucose level by enhancing insulin sensitivity and inhibit the production of reactive oxygen species by elevating the levels of antioxidant enzymes in diabetic heart. [15] Kumar et al. (2012) found fruit juice of E. officinalis (mixed with fresh bitter gourd juice) stimulate the islets of Langerhans. [16] Kumar et al. (2013) showed antidiabetic effects of aqueous extract of Curcuma longa rhizome in alloxan-induced diabetic rats. [17] Krishnaswamy (2008) found C. longa has increased plasma insulin and hepatic glucokinase activity levels in STZ-induced diabetic rats. [18] Rezq (2014) found that curcumin has pancreatic islet regeneration capacity in STZ-induced diabetic rats. [19] Singh et al. (2010) showed berberine reduces blood sugar by inhibiting absorption of sugars from the intestine. Furthermore, it enhances production of insulin. Mall et al. (2013) found that root bark powder of Berberis aristata stimulates pancreas to secret insulin. [20] All ingredients of Talapotaka Churna have different phytochemicals. [21] [22] [23] [24] It is believed that the basis of the chemical constitution of different herbal drugs and various medicinal/ plant extracts contain active flavonoids, alkaloids, phenolic compounds, terpenoids, saponins, and phytosterol type chemical constituents that are effective in the management of diabetic complications. This effect might be attributed to the amelioration of persistent hyperglycemia, oxidative stress, and modulations of the various metabolic pathways involved in the pathogenesis of diabetic complications. [25] In our study, Talapotaka Churna showed a significant decrease in blood sugar level both compared to a diabetic non-treated control group and to a group treated with a standard antidiabetic drug, glibenclamide in an animal model that replicated hyperglycemia. This study attempts to show that the mode of action of Talapotaka Churna may be similar to the mode of action of glibenclamide, i.e., by stimulating the pancreatic beta cells of the pancreas and increasing the sensitivity of the peripheral tissue to insulin. STZ caused selective destruction of insulin-secreting beta cells and raised blood sugar level in animals. [26] STZ, N-(methyl nitrocarbon)-D-glucosamine is a potent methylating agent for DNA and acts as nitric oxide donor in pancreatic β-cell, and thus β-cells are more sensitive to damage by nitric oxide and free radical scavenging enzyme. [27] 
CONCLUSION
Talapotaka Churna significantly decreases blood sugar level in experimental animals induced by STZ. Talapotaka Churna reduced blood sugar level gradually. The results suggest a protective role of Talapotaka Churna in STZ-induced hyperglycemia. The effect of two different doses of Talapotaka Churna and glibenclamide on fasting blood sugar in streptozotocin-induced albino rats, where values are given as mean ± standard deviation (n = 6 in each group). Values are statistically significant at P < 0.05, P < 0.001 compared with control group
